Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025

大腸癌治療薬の世界市場:治療、研究開発、市場予測

◆タイトル:Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025
◆商品コード:VGAIN5112513
◆調査・発行会社:visiongain
◆発行日:2015年11月
◆ページ数:114
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、大腸癌治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・大腸癌治療薬の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・大腸癌治療薬の世界市場:主要な医薬品
・大腸癌治療薬の世界市場:新薬
・大腸癌治療薬の世界市場:研究開発パイプライン
・大腸癌治療薬の世界市場:専門家の見解
・大腸癌治療薬の世界市場:主要企業分析
・結論

Colorectal Cancer Drugs – Your New Guide to that Market, its R&D and Sales Potentials
Do you want to assess the future of colorectal cancer medicines? Visiongain’s new report gives you revenue predictions for that industry from 2015, helping you stay ahead in knowledge and benefit your influence.

Our study shows you results, R&D trends, opportunities, interviews and revenue forecasts.

In that analysis you see predicted revenues to 2025 at overall world market, geographical and product level. You assess emerging trends, technologies and branded therapies. Explore the future of colorectal cancer drugs and their producers.

With our study, benefit your research, decisions, presentations and influence. Please read on now to discover how our new analysis can help your work.

Main ways Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025 helps you
In these six main ways, visiongain’s new analysis gives knowledge to make your work easier and faster, also benefiting your decisions and authority:
• Revenue forecasting of the overall world market and 5 geographical submarkets – assess outlooks for development, production, marketing and sales, seeing what is possible
• Nine leading drugs’ revenues to 2025 – find sales potentials for top brands, seeing how they can compete and succeed
• Profiles of leading companies – assess participants’ results, portfolios, capabilities, deals and outlooks
• R&D in colorectal cancer treatment – explore progress in research and development, finding technological, medical and commercial possibilities
• Interviews with two other authorities – discover opinions to help you stay ahead in knowledge, finding what companies say and do
• Analysis of what stimulates and restrains that pharma industry – assess challenges and opportunities, helping you gain advantages and succeed.

What forces stimulate the market for colorectal cancer treating medicines?
In 2015 there exist at least 158 agents in clinical development for colorectal cancer. A large number of those products are in phase II development. Our report helps you understand opportunities in that field and how to use them.

As ageing populations increase, the incidence of cancer rises, leading to rising spending on cancer-treating medicines. That trend will continue. Are you ready for those commercial opportunities? Let our study guide you, showing what is possible.

Gain data found nowhere else, benefiting your influence on those anticancer medicines
Visiongain’s study examines the colorectal cancer drugs market, using independent primary and secondary research. Gain discussions and data you find nowhere else.

In our new report you gain 35 charts, 29 tables and two research interviews to help you stay ahead in knowledge.

Forecasts for nine leading drugs – discover sales potentials
Our new investigation gives you revenue forecasts to 2025 for nine leading products for treating colorectal cancer:
• Avastin (Roche)
• Erbitux (BMS/Merck Serono)
• Xeloda (Roche)
• Vectibix (Amgen)
• Stivarga (Bayer)
• Eloxatin (Sanofi)
• TS-1 (Taiho Pharmaceuticals)
• Zaltrap (Sanofi)
• Cyramza (Eli Lilly)

In our work you also see profiles of leading companies and discussions of drugs in development. Our analysis explains activities and prospects of organisations developing, producing and marketing those therapies.

See what the future holds for products treating that disease. Our report explains, from 2015, pharma companies’ commercial prospects. Explore what the future holds.

Geographical markets – where lie the best sales and growth potentials?
Our survey also shows forecasts to 2025 for these five regions, showing overall colorectal cancer drug revenues:
• United States
• European Union
• Japan
• APAC
• Rest of the world.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Colorectal Cancer Drugs
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Colorectal Cancer and Treatments
2.1 Pathophysiology of Colorectal Cancer
2.2 Epidemiology of Colorectal Cancer
2.2.1 Incidence – Increases with Age
2.2.2 Mortality – Fourth-Leading Cause of Cancer Death
2.2.3 Survival – Depends on Stage of Cancer
2.3 Diagnosis – Benefits and Limitations
2.4 Treatment and Staging
2.4.1 Treatment Options
2.4.2 Staging in Colorectal Cancers
2.4.3 Treatment Depending on Stages

3. The World Colorectal Cancer Drugs Market, 2015-2025
3.1 Global Colorectal Cancer Drugs Market Forecast 2015-2025
3.2 Geographical Colorectal Cancer Drugs Market Forecasts 2015-2025
3.2.1 The US Colorectal Cancer Drugs Market, 2015-2025
3.2.1.1 The US Colorectal Cancer Drugs Market Forecast – Stagnant Growth
3.2.2 The Japanese Colorectal Cancer Drugs Market, 2015-2025
3.2.2.1 The Japanese Colorectal Cancer Drugs Market Forecast – High Price of Biosimilars Will Drive the Market
3.2.3 The EU Colorectal Cancer Drugs Market, 2015-2025
3.2.3.1 The EU Colorectal Cancer Drugs Market Forecast – Tough Regulatory Environment Will Slow Market Growth
3.2.4 The APAC Countries Colorectal Cancer Drugs Market, 2015-2025
3.2.4.1 The APAC Colorectal Cancer Drugs Market Forecast – Market Will Be Stimulated by Rising Incidence of Cancer Owing to Changes of Lifestyle
3.2.5 Rest of the World Colorectal Cancer Drugs Market, 2015-2025
3.2.5.1 Rest of the World Colorectal Cancer Drugs Market Forecast

4. The Top Colorectal Cancer Drugs: Revenue Forecasts, 2015-2025
4.1 Avastin (Roche)
4.1.1 Avastin Revenue Forecast – Leader of the Pack
4.1.2 Roche
4.2 Erbitux (BMS/Merck KGaA)
4.2.1 Erbitux Revenue Forecast – Will its Revenue be Eroded by Biosimilars?
4.2.2 BMS
4.2.3 Merck KGaA
4.3 Xeloda (Roche)
4.3.1 Xeloda Revenue Forecast – Declining Sharply
4.4 Vectibix (Amgen)
4.4.1 Vectibix Revenue Forecast – Sales Will Grow During the First Half of the Forecast Period
4.4.2 Amgen
4.5 Eloxatin (Sanofi)
4.5.1 Eloxatin Revenue Forecast – Declining Slowly
4.5.2 Sanofi
4.6 Zaltrap (Sanofi/Co-developed with Regeneron)
4.6.1 Zaltrap Revenue Forecast – Sales Expected to Grow Significantly Until 2020
4.7 Stivarga (Bayer)
4.7.1 Stivarga Revenue Forecast – Positive Growth Trend
4.7.2 Bayer
4.8 TS-1 (Taiho Pharmaceuticals)
4.8.1 TS-1 Revenue Forecast
4.8.2 Taiho Pharmaceuticals
4.9 Cyramza (Eli Lilly)
4.9.1 Cyramza Revenue Forecast – Additional Approval for mCRC Will Drive Sales
4.9.2 Eli Lilly

5. Emerging Therapies
5.1 Lonsurf (Taiho Pharmaceuticals) – Approved in Japan
5.2 Sym-004 (Symphogen) – Promising Results in Early Human Clinical Trials
5.3 IMMU-130/Labetuzumab-SN-38 (Immunomedics) – ADC with High Anti-Tumour Activity

6. R&D Pipelines for Colorectal Cancer Treatment
6.1 CPX-1 (Celator Pharmaceuticals) – Combination of Irinotecan HCl and Floxuridine
6.2 CT-011/Pidilizumab (CureTech) – Binds to PD-1
6.3 Dabrafenib/Tafinlar (GSK) – Inhibitor of B-Raf
6.4 E7820 (Eisai) – Inhibits Integrin Alpha 2
6.5 Entinostat (Syndax Pharmaceuticals) – Exhibits a Wide Range of Anti-Tumour Activity
6.6 Ganetespib (Synta Pharmaceuticals) – Inhibits Hsp90
6.7 LGX818/Encorafenib (Novartis) – Investigated in Several Trials
6.8 ABT-869/Linifanib (Abbott Laboratories) – Inhibits VEGF and PDGF Receptors
6.9 MORAb-004/Ontuxizumab (Morphotek, Inc.) – Targets Endosialin
6.10 Onartuzumab (Genentech) – Targets the Protein MET
6.11 JX-594 (SillaJen) – Oncolytic Virus
6.12 PF-05212384 (Pfizer) – PI3K/mTOR Inhibitor
6.13 Simtuzumab (Gilead) – Highly Selective for LOXL2
6.14 Talaporfin Sodium (Aptocine, Light Sciences Oncology) – Water-Soluble Drug
6.15 Tivantinib (ARQ 197; ArQule, Daiichi Sankyo) – An Option for EGFR-resistant MET-High mCRC Patients
6.16 Tivozanib (Astellas Pharma/Aveo Pharmaceuticals) – Inhibits VEGF Receptors
6.17 Trametinib (Mekinist, GlaxoSmithKline) – Blocks MEK1 and MEK2
6.18 Veliparib (ABT-888, AbbVie) – An Oral PARP
6.19 RG7221/ RO5520985/Vanucizumab (Roche) – Binds Ang2 and VEGF-A
6.20BKM-120/Buparlisib (Novartis) – Reduces Cellular Levels of Phosphorylated AKT
6.21 BYL-719/Alpelisib (Novartis)

7. Qualitative Analysis of the Colorectal-Cancer Drugs Market 2015-2025
7.1 SWOT Analysis of the Colorectal Cancer Drugs Market
7.1.1 Strengths
7.1.1.1 Rising Incidence of Cancer – Ageing Population
7.1.1.2 Multiple Treatment Options Are Usually Needed
7.1.2 Weaknesses
7.1.2.1 The Challenges of Drug Development
7.1.2.2 The Complex Nature of Cancer
7.1.3 Opportunities in the Cancer Drugs Market
7.1.3.1 The Advancement of Research
7.1.3.2 A Shift Towards Personalisation
7.1.4 Threats Facing the Cancer Drugs Market
7.1.4.1 The Threat of Regulation
7.2.1 Social Factors: The Cost of Living Longer
7.2.2 Technological Developments: Making the Market Move Forward
7.2.3 Economic Pressure: Treatment’s Hefty Price Tag
7.2.4 Political Issues: Governmental Involvement in Treatment

8. Research Interviews from Our Survey – 2015
8.1 Dr. Philip M. Arlen, President and CEO, Precision Biologics, Inc., US
8.1.1 Less Than 1% of Colonoscopies Screening Reveal Cancer
8.1.2 Market Driver – New Drugs with Novel MoA and Favourable Safety Profile
8.1.3 Ensituximab – Developed From a Tumour-Derived Cancer Vaccine
8.1.4 60% of Patients with Colorectal and Pancreatic Cancer Express the Ensituximab Target
8.2 Dr. John Beadle, CEO of PsiOxus Therapeutics, UK
8.2.1 Significant Unmet Need – Effective Treatments for MSI Normal and MSI Low Patients
8.2.2 Checkpoint Inhibitors – Work Well in MSI High Patients
8.2.3 Enadenotucirev Remains Stable in Human Blood
8.2.4 Enadenotucirev – Positioning in the Colorectal Cancer Market?

9. Conclusions of the Study
9.1 Patent Expiries and the Impact of Biosimilars
9.2 The US – Still the Largest National Market
9.3 APAC – Will Show the Fastest Growth
9.4 Colorectal Cancer Drugs R&D Pipeline – Crowded, but How Many Promising Drugs?
9.5 Concluding Remarks

List of Tables
Table 1.1 Forecast Regional and National Colorectal Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2015-2025
Table 2.1 Benefits and Limitations of Diagnostic Tests for Colorectal Cancer
Table 3.1 Global Colorectal Cancer Drug Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.2 Leading National and Regional Colorectal Cancer Drug Markets: Revenue Forecasts ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2015-2025
Table 3.3 The US Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.4 The Japanese Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.5 The EU Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.6 APAC Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.7 RoW Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.1 Top Colorectal Cancer Drugs: Revenue ($bn) and Market Share (%), 2014
Table 4.2 Top 9 Colorectal Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2014, 2019, 2025
Table 4.3 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.4 Roche – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 4.5 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.6 Bristol-Myers Squibb – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 4.7 Merck KGaA– Revenue ($bn), Change (%) and Share (%), 2014
Table 4.8 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.9 Vectibix Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.10 Amgen – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 4.11 Eloxatin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.12 Sanofi–Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 4.13 Zaltrap Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.14 Stivarga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.15 Bayer– Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 4.16 TS-1 Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.17 Taiho Pharmaceutical– Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 4.18 Cyramza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.19 Eli Lilly – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the Colorectal Cancer Drugs Market, 2015
Table 7.2 Social, Technological, Economic and Political Analysis of the Colorectal Cancer Drugs Market, 2015

List of Figures
Figure 2.1 Current Standard Treatment Options for Metastatic Colorectal Cancer
Figure 3.1 Global Colorectal Cancer Drug Market: Revenue Forecast ($bn), 2015-2025
Figure 3.2 Global Colorectal Cancer Drugs Market: Drivers and Restraints, 2015-2025
Figure 3.3 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2014
Figure 3.4 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2019
Figure 3.5 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2025
Figure 3.6 Developed National Markets: Drivers and Restraints, 2015-2025
Figure 3.7 The US Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 3.8 The Japanese Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 3.9 The EU Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 3.10 APAC Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 3.11 Emerging National Markets: Drivers and Restraints, 2015-2025
Figure 3.12 RoW Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
Figure 4.1 Top 9 Colorectal Cancer Drugs: Market Share (%), 2014
Figure 4.2 Top 9 Colorectal Cancer Drugs: Market Share (%), 2019
Figure 4.3 Top 9 Colorectal-Cancer Drugs: Market Share (%), 2025
Figure 4.4 Avastin Revenue Share by Indication (%), 2014
Figure 4.5 Avastin Revenue Forecast ($bn), 2015-2025
Figure 4.6 Roche’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
Figure 4.7 Erbitux Revenue Forecast ($bn), 2015-2025
Figure 4.8 Bristol-Myers Squibb’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
Figure 4.9 Merck KGaA’s Drug by Share of Company Revenue (%), 2014
Figure 4.10 Xeloda Revenue Forecast ($bn), 2015-2025
Figure 4.11 Vectibix Revenue Forecast ($bn), 2015-2025
Figure 4.12 Amgen’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
Figure 4.13 Eloxatin Revenue Forecast ($bn), 2015-2025
Figure 4.14 Sanofi’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
Figure 4.15 Zaltrap Revenue Forecast ($bn), 2015-2025
Figure 4.16 Stivarga Revenue Forecast ($bn), 2015-2025
Figure 4.17 Bayer’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
Figure 4.18 TS-1Revenue Forecast ($bn), 2015-2025
Figure 4.19 Taiho Pharmaceutical Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
Figure 4.20 Cyramza Revenue Forecast ($bn), 2015-2025
Figure 4.21 Eli Lilly’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
Figure 9.1 Top 9 Colorectal Cancer Drugs: Revenues ($bn), 2014, 2019, 2025

【レポートのキーワード】

大腸癌、大腸癌治療薬、医薬品、研究開発

★調査レポート[大腸癌治療薬の世界市場:治療、研究開発、市場予測] ( Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025 / VGAIN5112513) 販売に関する免責事項
[大腸癌治療薬の世界市場:治療、研究開発、市場予測] ( Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025 / VGAIN5112513) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆